Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
Most relevant news about ULTRAGENYX PHARMACEUTICAL
10/18Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/17Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
08/30Ultragenyx to Present at Upcoming Investor Conferences
GL
08/30ULTRAGENYX PHARMACEUTICAL : FDA clarifies path to submission for Ultragenyx's ra..
AQ
08/29ULTRAGENYX PHARMACEUTICAL : Announces FDA Accepts Proposal to Submit an NDA for ..
AQ
08/28ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Europe for the Tre..
AQ
08/27Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europ..
GL
08/03ULTRAGENYX : 2Q Earnings Snapshot
AQ
08/02Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
GL
07/31ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Second Quarter 2018 Fina..
AQ
More most relevant news
All news about ULTRAGENYX PHARMACEUTICAL
10/18Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazi..
GL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/19ULTRAGENYX PHARMACEUTICAL : appoints Dr. Wladimir Hogenhuis as COO
AQ
09/17ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers, Fina..
AQ
09/17Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
More news
Sector news : Bio Therapeutic Drugs
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/27Ultragenyx's DTX301 shows positive effect in OTC study 
09/17Ultragenyx appoints Dr. Wladimir Hogenhuis as COO 
09/10Premarket analyst action - healthcare 
09/05Gene therapy players under pressure 
08/29YOUR DAILY PHARMA SCOOP : ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozemp.. 
08/29Ultragenyx up 3% premarket on FDA sign-off early filing of NDA for UX007 
Latest Tweets
10/18Want automatic email alerts for $ACSF $SC $CELP $RARE $DRNA? Subscribe to Mar.. 
10/18Anyone who's been long since around the time of the IPO w/ $RARE $RVNC $ATRA .. 
10/16Ultragenyx Pharmaceutical $RARE Downgraded to Buy at ValuEngine  
10/15DOWNSIDE MOMENTUM ALERT: $RARE ULTRAGENYX PHARMACEUTICALS INC ? TradeIdeas vi.. 
10/13Ultragenyx Pharmaceutical $RARE Downgraded by ValuEngine  
More tweets
Qtime:78
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,8x
EV / Sales 2019 27,8x
Capitalization 3 219 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 219
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222